Kurz gefasst
Fachartikel in der Zeitschrift Science, 2024. Verfasst von Daniel J Drucker. Beteiligte Einrichtung: The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Cardiovascular System, Glucagon-Like Peptide 1, Glucagon-Like Peptides, Weight Loss. Die Arbeit wurde bisher 172-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Glucagon-like peptide–1–based medicines have weight loss–independent actions
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Cardiovascular SystemGlucagon-Like Peptide 1Glucagon-Like PeptidesWeight LossHumansDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsLiraglutideMyocardial IschemiaAnimalsSemaglutide
Substanzen
Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesLiraglutideSemaglutide
Autor:innen und Institutionen
- The Lunenfeld-Tanenbaum Research Institute, Mt. Sinai Hospital, and the Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Zitieren
APA
Drucker, D. J. (2024). The benefits of GLP-1 drugs beyond obesity. Science. https://doi.org/10.1126/science.adn4128
Vancouver
Drucker DJ. The benefits of GLP-1 drugs beyond obesity. Science. 2024. doi:10.1126/science.adn4128
BibTeX
@article{Drucker2024,
author = {Drucker, Daniel J},
title = {The benefits of GLP-1 drugs beyond obesity},
journal = {Science},
year = {2024},
doi = {10.1126/science.adn4128}
}
EUVIMED